Loading the SOTA2 catalog…
InVision Medical Technology
Develops clinically-validated AI for echocardiography, streamlining interpretation, standardizing measurements, and surfacing undiagnosed disease. Founded and led by clinicians and computer scientists from Stanford and Cedars-Sinai. Backed by Y Combinator and strategic partners including Alexion, AstraZeneca Rare Disease, with live deployments through partners like HeartLab.
- Founded
- 2022
- Headquarters
- San Francisco
- Company size
- 1–10
- Products tracked
- 6
Products by InVision Medical Technology
Rankings
Appears in these rankings
Customer voice
Customer testimonials
Quotes published on InVision Medical Technology's official website.
We aspire to prevent misdiagnosis of rare diseases, democratize expert knowledge to more clinicians, and ensure that excellent care is available to every patient — in every clinical setting.
We wanted a partner with real evidence — not a pilot in search of a publication. InVision arrived with the Nature paper, the FDA clearance, and a deployment plan. That's a different conversation.
Pricing for InVision Medical Technology
Contact sales
Contact InVision Medical Technology for current plans, volume pricing, and enterprise terms.
Trust profile
Security and compliance
SOC 2
ISO 9001
HIPAA
FDA 510(k) Clearance — Precision LVEF
FDA 510(k) Clearance — Precision Cardiac Amyloid
FDA Breakthrough Device Designation — Precision Cardiac Amyloid
FDA Breakthrough Device Designation — Precision Cirrhosis
FDA Total Product Lifecycle Advisory Program (TAP) — Precision Cardiac Amyloid
CPT Category III code 0932T (effective January 1, 2025) — Precision Cardiac Amyloid
DICOM Part 15 compliance — Automatic DICOM Deidentification
Session-only cookies (no persistent cookies)
Commercially reasonable physical, managerial, and technical safeguards
Security breach notification to affected users
Third-party processors required to use reasonable confidentiality measures and comply with Privacy Policy